Top

Published in:

01-03-2013 | Original Article

Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases

Authors: Koji Habe, Hideo Wada, Takeshi Matsumoto, Kohshi Ohishi, Makoto Ikejiri, Kimiko Matsubara, Tatsuhiko Morioka, Yuki Kamimoto, Tomoaki Ikeda, Naoyuki Katayama, Tsutomu Nobori, Hitoshi Mizutani

Published in: International Journal of Hematology | Issue 3/2013

Abstract

Antiphospholipid antibodies (aPL) including lupus anticoagulant (LA), anticardiolipin antibodies (aCL) IgG and aCL-β2-glycoprotein I (β2GPI) complex IG are causative factors for thrombotic event (THE). We retrospectively investigated relationships between aPLs and THE in 458 patients suspected of having antiphospholipid syndrome. THEs were observed in 232 of 458 patients, including 148 cases of venous thrombosis, 59 of arterial thrombosis, 18 of microthrombosis, and 20 of complications of pregnancy. The frequency of THE was significantly high in patients positive for LA and/or aPL. In patients with autoimmune disease (AID), the frequency of THE was significantly high in patients with any types of aPLs. Additionally, risk of THE was significantly increased in patients with more than two types of aPLs. Prolonged activated partial thromboplastin time indicated a high risk for THE. However, neither thrombocytopenia nor AID was a risk for THE. In conclusion, the presence of aPL is an indicator for high risk of THE in patients in whom THE was suspected. However, the risk of THE in aPL-positive patients varied among patients with different underlying diseases.

Palomo IG, Segovia FM, Alarcon ML, Fuentes BY, Pereira JG, Rojas A, Forastiero R. An insight into the pathophysiology of thrombosis in antiphospholipid syndrome. Front Biosci. 2007;12:3093–103.PubMedCrossRef

Staub HL, Bertolaccini ML, Munther MA: Anti-phosphatidyl- ethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun. Rev. 2012;52:804–10.

Muscal E, Brey RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus. 2010;19:406–11.PubMedCrossRef

Hughes G. Hughes Syndrome: the antiphospholipid syndrome–a clinical overview. Clin Rev Allergy Immunol. 2007;32:3–12.PubMedCrossRef

Chandramouli NB, Rodgers GM. Management of thrombosis in women with antiphospholipid syndrome. Clin Obstet Gynecol. 2001;44:36–47.PubMedCrossRef

Boyanovski B, Russeva M, Dobreva G, Ganev V, Mladenova A, Peicheva V, Nikolov K, Baleva M. Protein C Activity in patients with antiphospholipid syndrome. J Clin Rheumatol. 2000;6:239–43.PubMedCrossRef

Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010;47:2170–5.PubMedCrossRef

Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12:53–7.PubMedCrossRef

Samarkos M, Mylona E, Kapsimali V. The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity. Semin Arthritis Rheum. 2012;42:66–9.PubMedCrossRef

10.

Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498–509.PubMedCrossRef

11.

Ortel TL. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. Am J Hematol. 2012;87:S75–81.PubMedCrossRef

12.

Avcin T, Silverman ED. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus. 2007;16:627–33.PubMedCrossRef

13.

Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus. 2005;14:499–504.PubMedCrossRef

14.

Kaburaki J, Kuwana M, Ikeda Y: Anti-cardiolipin-beta2-GPI complex antibodies in idiopathic thrombocytopenic purpura. Intern Med. 1998; 37:796. (author reply 797–8).

15.

Muñoz-Rodriguez FJ, Font J, Cervera R, Reverter JC, Tàssies D, Espinosa G, López-Soto A, Carmona F, Balasch J, Ordinas A, Ingelmo M. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum. 1999;29:182–90.PubMedCrossRef

16.

Jennings I, Kitchen S, Kitchen DP, Woods TA, Walker ID. ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories? J Thromb Haemost. 2011;9:2117–9.PubMedCrossRef

17.

Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International society on thrombosis and haemostasis (ISTH). Thromb Haemost. 2001;86:1327–30.

18.

Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:631–40.

19.

Kandiah DA, Krilis SA. Heterogeneity of lupus anticoagulant (LA) antibodies: LA activity in dilute Russell’s viper venom time and dilute kaolin clotting time detect different populations of antibodies in patients with the “antiphospholipid” syndrome. Thromb Haemost. 1998;80:250–7.PubMed

20.

Pengo V, Denas G, Bison E, Banzato A, Jose SP, Gresele P, Marongiu F, Erba N, Veschi F, Ghirarduzzi A, De Candia E, Montaruli B, Marietta M, Testa S, Barcellona D, Tripodi A, Italian Federation of Thrombosis Centers (FCSA). Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with lupus anticoagulant (LA). Thromb Res. 2010;126:150–3.PubMedCrossRef

21.

Diz-Küçükkaya R, Hacihanefioğlu A, Yenerel M, Turgut M, Keskin H, Nalçaci M, Inanç M. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98:1760–4.PubMedCrossRef

22.

De Laat B, Derksen RH, Reber G, Musial J, Swadzba J, Bozic B, Cucnik S, Regnault V, Forastiero R, Woodhams BJ, De Groot PG. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost. 2011;9:149–53.PubMedCrossRef

23.

Pengo V. APS—controversies in diagnosis and management, critical overview of current guidelines. Thromb Res. 2011;127:S51–2.PubMedCrossRef

24.

Deng X, Liu X. Reevaluation of predictive value of ACL and anti-2GP1 antibody for thrombosis in patients with systemic lupus erythematosus: from a perspective of a practical world. Rheumatol Int. 2012;32:3881–6.PubMedCrossRef

25.

Sciascia S, Murru V, Sanna G, Roccatello D, A Khamashta M, Laura Bertolaccini M: Clinical accuracy for diagnosis of Antiphospholipid Syndrome in SLE: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost. 2012;10:2512-8.

26.

Nojima J. Advanced clinical laboratory studies in the graduate school of medicine—studies on pathogenic mechanisms of anti-phospholipid syndrome. Rinsho Byori. 2009;57:786–92.PubMed

27.

Fujieda Y, Atsumi T, Amengual O, Odani T, Otomo K, Kato M, Oku K, Kon Y, Horita T, Yasuda S, Koike T. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus. 2012;21:1506–14.PubMedCrossRef

Title: Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases
Authors: Koji Habe
Hideo Wada
Takeshi Matsumoto
Kohshi Ohishi
Makoto Ikejiri
Kimiko Matsubara
Tatsuhiko Morioka
Yuki Kamimoto
Tomoaki Ikeda
Naoyuki Katayama
Tsutomu Nobori
Hitoshi Mizutani
Publication date: 01-03-2013
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 3/2013
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-013-1277-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Clinical significance of jejunoileal involvement of non-Hodgkin’s lymphoma detected by double-balloon enteroscopy

Multiple myeloma-initiating cells

Current approaches for the treatment of multiple myeloma

JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients

Molecular pathogenesis of multiple myeloma: basic and clinical updates

A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer